NOV 08, 2017 6:00 AM PST

How to Monitor Heparin Therapy: Still a Controversy

Speaker
  • Clinical Research Scientist, 59th CRD
    Biography
      David L. McGlasson, MS. MLS(ASCP)cm was a staff researcher at the 59th Clinical Research Division at Lackland JBSA in San Antonio, TX until his retirement.. He has published 166 abstracts, 76 manuscripts, 9 book chapters, three patents and one book. Mr. McGlasson has also presented more than 200 lectures at local, state, national and international levels. He is the 9 time winner of the American Clinical Laboratory Science Award for scientific research and has received the Kendall-Sherwood Award, the Bio-Rad award for scientific achievement in Hematology. He also has won numerous poster competitions at many meetings. To include the Society of Armed Forces Laboratory Science, International Society of Thrombosis and Hemostasis and American Society of Clinical Laboratory Science. He currently is a consulatant in the area of Hemostasis and Thrombosis.

    Abstract

    Monitoring unfractionated heparin (UFH) using the activated partial thromboplastin time (APTT) or the anti-factor Xa (anti-Xa) chromogenic assay still seems to be a controversy.  Is the anti-Xa less affected by pre-analytical variables in monitoring subjects on UFH and the low molecular weight heparins (LMWH)?  Which assay is more accurate in monitoring heparin to achieve therapeutic levels, cost effective in time spent monitoring patients, use of blood products, time in the hospital, and overall cost which may include laboratory testing time.  The APTT still is the most commonly used assay to monitor UFH therapy but cannot be used to monitor the LMWHs.  Previous studies have cited interference in monitoring UFH with the  APTT from oral anticoagulants, oral contraceptives, lupus anticoagulants, factor deficiencies, elevated acute phase reactants (fibrinogen, FVIII), low anti-thrombin, the APTT reagent sensitivity and instrumentation.  The anti-Xa assay may be affected by hyperbilirubinemia, hyperlipidemia (can be cleared by ultracentrifugation) and decreased anti-thrombin levels (assay dependent). The anti-Xa assay can be used to monitor all heparin analogues and direct oral anticoagulants (DOACs).  This presentation will discuss the pros and cons of both methods and which may be most effective in patient care.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    APR 21, 2021 10:00 AM PDT
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    MAR 25, 2021 8:00 AM PDT
    C.E. CREDITS
    MAR 25, 2021 8:00 AM PDT
    Date: March 25, 2021 Time: 8:00am (PST), 11:00am (EST) Flow cytometry has expanded to have more users, more data, and multiple instrument types. While this has lead to more quantitative data...
    APR 20, 2021 11:00 AM PDT
    C.E. CREDITS
    APR 20, 2021 11:00 AM PDT
    Date: April 20, 2021 Time: 11:00am (PST), 2:00pm (EST) Identification and confirmation of microbial isolates is crucial in the analysis workflow, providing decision-makers the information...
    DEC 15, 2020 10:00 AM PST
    C.E. CREDITS
    DEC 15, 2020 10:00 AM PST
    DATE: December 15, 2020 TIME: 10:00am PST Scientists from Thermo Fisher Scientific will walk us through the world of microorganisms. They will discuss their most recent research on viruses,...
    NOV 08, 2017 6:00 AM PST

    How to Monitor Heparin Therapy: Still a Controversy


    Specialty

    Laboratory Testing

    Immunology

    Molecular Biology

    Infectious Disease

    Antibodies

    Hematology

    Molecular Diagnostics

    Lab Automation

    Genomics

    Coagulation Tests

    Biomarkers

    Oncology

    Microbiology

    Research

    Pcr/rt-Pcr/real-Time Pcr

    Geography

    North America80%

    Registration Source

    Website Visitors100%

    Job Title

    Clinical Laboratory Scientist100%

    Organization

    Hospital40%

    Medical Center20%

    Medical Device Company20%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more